Antimetastatic Molecules: Perspective towards Treatment of Solid Cancers
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 2409
Special Issue Editor
Interests: anti-cancer drugs; antibiotics; antibacterial agents; bacterial infections; drug-resistant pathogens; medicinal chemistry; natural products; rational drug design; repurposing existing drugs and drug targets
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer metastasis is the major cause of cancer morbidity and mortality and accounts for about 90% of cancer deaths. FDA-approved cytotoxic anticancer drugs have proven difficult in treating metastatic solid cancers. Metastatic solid cancer cells can invade via protease-dependent mesenchymal migration or protease-independent amoeboid migration. Many cancer cells can switch between these invasion modes in response to changes in the surrounding environment or to escape from cancer chemotherapies. As a general concept, treatment of metastatic solid cancers should be complemented with drugs that inhibit the ability of cancer cells to invade through the extracellular matrix and establish secondary tumors. The newer anticancer drugs developed based on the aberrant expression of molecular targets in cancer cells are cytotoxic molecules. Treatment with cytotoxic drugs is associated with common side effects. Immunotherapy is a promising method for the prevention and treatment of metastatic cancers. However, its therapeutic efficacies and adverse effects on the treatment of metastatic solid cancers need to be further studied. Thus, the discovery of a novel molecular target, which can develop into an antimetastatic agent with low toxicity to healthy cells, is a challenging goal for anticancer drug discovery. The aim of this Special Issue is to cover advances in the discovery of antimetastatic anticancer drugs. This Special Issue may include original research articles and reviews on drug targets, medicinal chemistry, new chemical entities, the structural biochemistry of unexploited drug targets, immunotherapy, new formulations, drug delivery, and new strategies for using approved drugs.
Prof. Dr. Michio Kurosu
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antimetastatic molecules
- metastatic cancers
- tumor metastasis
- epithelial-mesenchymal transition (EMT)
- cell-cell adhesion
- integrin adhesions
- chemotherapeutic drugs
